Brokers Offer Predictions for Legend Biotech Q4 Earnings

Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) – Analysts at HC Wainwright dropped their Q4 2026 EPS estimates for shares of Legend Biotech in a report released on Wednesday, July 15th. HC Wainwright analyst M. Kapoor now expects that the company will post earnings per share of $0.22 for the quarter, down from their prior estimate of $0.26. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Legend Biotech’s current full-year earnings is ($0.01) per share.

Legend Biotech (NASDAQ:LEGN) last posted its earnings results on Wednesday, May 13th. The company reported ($0.03) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.01). Legend Biotech had a negative net margin of 21.98% and a negative return on equity of 24.92%. The business had revenue of $305.10 million during the quarter, compared to analysts’ expectations of $306.51 million. During the same period last year, the company earned ($0.07) EPS. The business’s quarterly revenue was up 56.5% compared to the same quarter last year.

A number of other research analysts also recently commented on the company. Weiss Ratings downgraded Legend Biotech from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, July 10th. UBS Group boosted their target price on Legend Biotech from $31.00 to $49.00 and gave the stock a “buy” rating in a research note on Wednesday, June 3rd. Royal Bank Of Canada lowered their price target on Legend Biotech from $64.00 to $63.00 and set an “outperform” rating for the company in a report on Tuesday, July 7th. JPMorgan Chase & Co. began coverage on shares of Legend Biotech in a research note on Monday. They issued a “neutral” rating and a $35.00 price target on the stock. Finally, TD Cowen boosted their price objective on shares of Legend Biotech to $29.00 and gave the stock a “hold” rating in a research report on Wednesday, May 13th. Nine equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $57.00.

Legend Biotech Price Performance

Shares of NASDAQ LEGN opened at $22.71 on Friday. The company has a market capitalization of $4.22 billion, a price-to-earnings ratio of -33.40 and a beta of 0.34. The business has a 50-day moving average of $29.44 and a two-hundred day moving average of $23.33. Legend Biotech has a 1 year low of $16.24 and a 1 year high of $45.30.

Institutional Investors Weigh In On Legend Biotech

Several large investors have recently modified their holdings of LEGN. Assenagon Asset Management S.A. purchased a new position in shares of Legend Biotech during the second quarter worth approximately $55,307,000. Avior Wealth Management LLC acquired a new stake in Legend Biotech during the 2nd quarter worth $235,000. Parallel Advisors LLC grew its position in Legend Biotech by 173.9% during the 1st quarter. Parallel Advisors LLC now owns 2,084 shares of the company’s stock worth $38,000 after purchasing an additional 1,323 shares during the last quarter. Avidity Partners Management LP purchased a new position in Legend Biotech during the 1st quarter worth $271,000. Finally, ADAR1 Capital Management LLC acquired a new position in Legend Biotech in the first quarter valued at $362,000. 70.89% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Legend Biotech

In other Legend Biotech news, CEO Ying Huang sold 5,566 shares of Legend Biotech stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $14.78, for a total transaction of $82,265.48. Following the transaction, the chief executive officer owned 241,872 shares of the company’s stock, valued at $3,574,868.16. The trade was a 2.25% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 0.02% of the stock is owned by corporate insiders.

About Legend Biotech

Legend Biotech (NASDAQ: LEGN) is a commercial-stage biopharmaceutical company specializing in the development and commercialization of chimeric antigen receptor T-cell (CAR-T) therapies for oncology. Headquartered in Somerset, New Jersey, with research and development operations in Shanghai, the company leverages a global infrastructure to advance innovative cellular therapies. Legend Biotech pursues a strategy of strategic collaboration to extend its reach, most notably through its partnership with Janssen Biotech, a subsidiary of Johnson & Johnson.

The company’s lead asset, ciltacabtagene autoleucel (commercially marketed as Carvykti), is a B-cell maturation antigen (BCMA)–directed CAR-T therapy for the treatment of relapsed or refractory multiple myeloma.